Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been given an average rating of “Buy” by the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $46.43.
A number of brokerages recently commented on DNTH. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock.
View Our Latest Report on DNTH
Hedge Funds Weigh In On Dianthus Therapeutics
Dianthus Therapeutics Stock Up 6.4 %
NASDAQ DNTH opened at $23.20 on Friday. The company has a 50-day moving average price of $24.77 and a 200-day moving average price of $26.57. Dianthus Therapeutics has a 52 week low of $10.65 and a 52 week high of $33.77. The firm has a market capitalization of $686.65 million, a P/E ratio of -9.28 and a beta of 1.75.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
- Five stocks we like better than Dianthus Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- Using the MarketBeat Dividend Yield Calculator
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- What is an Earnings Surprise?
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.